The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Advanced siRNA Designs Further Improve In Vivo Performance of GalNAc-siRNA Conjugates
Open accessAbstract
Significant progress has been made in the advancement of RNAi therapeutics by combining a synthetic triantennary N-acetylgalactosamine ligand targeting the asialoglycoprotein receptor with chemically modified small interfering RNA (siRNA) designs, including the recently described Enhanced Stabilization Chemistry. This strategy has demonstrated robust RNAi-mediated gene silencing in liver after subcutaneous administration across species, including human. Here we demonstrate that substantial efficacy improvements can be achieved through further refinement of siRNA chemistry, optimizing the positioning of 2'-deoxy-2'-fluoro and 2'-O-methyl ribosugar modifications across both strands of the double-stranded siRNA duplex to enhance stability without compromising intrinsic RNAi activity. To achieve this, we employed an iterative screening approach across multiple siRNAs to arrive at advanced designs with low 2'-deoxy-2'-fluoro content that yield significantly improved potency and duration in preclinical species, including non-human primate. Liver exposure data indicate that the improvement in potency is predominantly due to increased metabolic stability of the siRNA conjugates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The naturally occurring RNAi pathway can also be harnessed in extrahepatic organs by building on nearly two decades of efforts on liver siRNA design optimization [9][10][11][12] ; however, novel delivery approaches are needed.”
From Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates (2022) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Next, we evaluated other siRNA design elements and con rmed that full chemical modi cation with strategic placement of 2'-uoro and 2'-O-methyl modi cations 9 is required for robust siRNA activity in the CNS.”
From Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates (2022) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“2'-O-C16 was well tolerated across both strands, with potency similar to the unconjugated siRNA, except for a few positions known to be sensitive to sterically demanding 2'-modi cations 9 .”
From Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates (2022) · cites this paper as [9]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
Hannon, G. J. (2002) · Nature · doi:10.1038/418244a · Cited by 3,651
Nair, J. K., Willoughby, J. L. S., Chan, A., Charisse, K., Alam, M. R., Wang, Q., Hoekstra, M., Kandasamy, P., Kel’in, A. V., Milstein, S., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja505986a · Cited by 1,141
Self-citationSafety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971
Self-citationsiRNA function in RNAi: A chemical modification analysis
Chiu, Y., & Rana, T. M. (2003) · RNA · doi:10.1261/rna.5103703 · Cited by 863
Knocking down disease: a progress report on siRNA therapeutics
Wittrup, A., & Lieberman, J. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3978 · Cited by 827
A highly durable RNAi therapeutic inhibitor of PCSK9
Fitzgerald, K., White, S., Borodovsky, A., Bettencourt, B. R., Strahs, A., Clausen, V., Wijngaard, P., Horton, J. D., Taubel, J., Brooks, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609243 · Cited by 768
Frank-Kamenetsky, M. D., Grefhorst, A., Anderson, N. N., Racie, T., Bramlage, B., Akinc, A., Butler, D., Charissé, K., Dorkin, J. R., Fan, Y., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805434105 · Cited by 644
Self-citationFitzgerald, K. J., Frank-Kamenetsky, M. D., Shulga‐Morskaya, S., Liebow, A., Bettencourt, B. R., Sutherland, J. E., Hutabarat, R. M., Clausen, V. A., Karsten, V., Cehelsky, J. E., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61914-5 · Cited by 586
Flagged first, then by citations
1 of the 32 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–200 of 327
Schlegel, M. K., Matsuda, S., Brown, C. R., Harp, J. M., Barry, J. D., Berman, D., Castoreno, A. B., Schofield, S., Szeto, J., Manoharan, M., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab916 · Cited by 37
Self-citationGarreau, M., Weidner, J., Hamilton, R. S., Kołosionek, E., Toki, N., Stavenhagen, K., Paris, C., Bonetti, A., Czechtizky, W., Gnerlich, F. A., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae141 · Cited by 38
Novel Pharmacological Approaches in the Treatment of Hypertension: A Focus on RNA-Based Therapeutics
Addison, M., Ranasinghe, P. D., & Webb, D. J. (2023) · Hypertension · doi:10.1161/hypertensionaha.122.19430 · Cited by 37
Trends in Therapeutic Conjugates: Bench to Clinic
Rudra, A., Li, J., Shakur, R., Bhagchandani, S. H., & Langer, R. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00828 · Cited by 36
GalNAc-siRNA conjugates: Prospective tools on the frontier of anti-viral therapeutics
Thangamani, L., Balasubramanian, B., Easwaran, M., Natarajan, J., Pushparaj, K., Meyyazhagan, A., & Piramanayagam, S. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105864 · Cited by 37
Yang, X., Wang, Y., Chen, S., Zhang, S., & Cui, C. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s332830 · Cited by 35
Gene targeting as a therapeutic avenue in diseases mediated by the complement alternative pathway
Dreismann, A. K., Hallam, T. M., Tam, L. C. S., Nguyen, C. V., Hughes, J. P., Ellis, S., & Harris, C. L. (2022) · Immunological Reviews · doi:10.1111/imr.13149 · Cited by 36
Humphreys, S. C., Thayer, M. B., Campbell, J., Chen, W. L. K., Adams, D. J., Lade, J. M., & Rock, B. M. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01839 · Cited by 34
Special Section on Pharmacokinetic and Drug Metabolism Properties of Novel Therapeutic Modalities
Ramsden, D., Wu, J., Zerler, B. R., Iqbal, S., Jiang, J., Clausen, V. A., Aluri, K. C., Gu, Y., Dennin, S., Kim, J., et al. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.119.087098 · Cited by 34
Therapeutic RNA interference: A novel approach to the treatment of primary hyperoxaluria
Forbes, T. A., Brown, B. D., & Lai, C.-J. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14925 · Cited by 33
GalNac-siRNA conjugate delivery technology promotes the treatment of typical chronic liver diseases
Qin, Z.-X., Zuo, L., Zeng, Z., Ma, R., Xie, W., Zhu, X., & Zhou, X. (2025) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2025.2466767 · Cited by 32
Counteracting Angiotensinogen Small-Interfering RNA-Mediated Antihypertensive Effects With REVERSIR
Ye, D., Cruz‐López, E. O., van Veghel, R., Garrelds, I. M., Kasper, A., Wassarman, K., Tu, H.-C., Zlatev, I., & Danser, A. H. J. (2024) · Hypertension · doi:10.1161/hypertensionaha.124.22878 · Cited by 36
A first-in-class EGFR-directed KRAS G12V selective inhibitor
Stanland, L. J., Huggins, H. P., Sahoo, S. S., Porrello, A., Chareddy, Y. S., Azam, S. H., Perry, J. L., Pallan, P. S., Whately, K. M., Edatt, L., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.05.016 · Cited by 34
RNA Interference-Based Cancer Drugs: The Roadblocks, and the “Delivery” of the Promise
Das, M., Musetti, S., & Huang, L. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0762 · Cited by 31
IL4‐Receptor‐Targeted Dual Antitumoral Apoptotic Peptide—siRNA Conjugate Lipoplexes
Luo, J., Höhn, M., Reinhard, S., Loy, D. M., Klein, P. M., & Wagner, E. (2019) · Advanced Functional Materials · doi:10.1002/adfm.201900697 · Cited by 31
Distribution and biotransformation of therapeutic antisense oligonucleotides and conjugates
Weidolf, L. O. G., Björkbom, A., Dahlén, A., Elebring, M., Gennemark, P., Hölttä, M., Janzén, D. L. I., Li, X., & Andersson, S. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.04.002 · Cited by 31
Abosalha, A. K., Ahmad, W., Boyajian, J. L., Islam, P., Ghebretatios, M., Schaly, S., Thareja, R., Arora, K., & Prakash, S. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2155630 · Cited by 33
Small circular interfering RNAs (sciRNAs) as a potent therapeutic platform for gene-silencing
Jahns, H., Degaonkar, R., Podbevšek, P., Gupta, S., Bisbe, A., Aluri, K. C., Szeto, J., Kumar, P., LeBlanc, S., Racie, T., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab724 · Cited by 33
Self-citationCastellanos-Rizaldos, E., Brown, C. R., Dennin, S., Kim, J., Gupta, S., Najarian, D., Gu, Y., Aluri, K. C., Enders, J., Brown, K. M., et al. (2020) · Nucleic Acid Therapeutics · doi:10.1089/nat.2019.0840 · Cited by 33
Self-citationNaito, M., Chaya, H., Toh, K., Kim, B. S., Hayashi, K., Fukushima, S., Nagata, T., Yokota, T., Kataoka, K., & Miyata, K. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.01.001 · Cited by 30
Plasma and Liver Protein Binding of N-Acetylgalactosamine–Conjugated Small Interfering RNA
Humphreys, S. C., Thayer, M. B., Lade, J. M., Wu, B., Sham, K. K. C., Basiri, B., Hao, Y., Huang, X. Y., Smith, R. J., & Rock, B. M. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.119.086967 · Cited by 29
Oligonucleotide therapeutics and their chemical modification strategies for clinical applications
Kim, H., Kim, S., Lee, D., Lee, D., Yoon, J., & Lee, H. (2024) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-024-00669-8 · Cited by 30
Down syndrome and DYRK1A overexpression: relationships and future therapeutic directions
Murphy, A. J., Wilton, S. D., Aung-Htut, M. T., & McIntosh, C. S. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2024.1391564 · Cited by 28
Ren, Y., Lyu, J., Guo, Y., Yuan, Y., & Hu, L. (2022) · Journal of Immunology Research · doi:10.1155/2022/9557859 · Cited by 28
Li, J., Liu, J., Enders, J., Arciprete, M., Tran, C., Aluri, K. C., Guan, L.-H., O′Shea, J., Bisbe, A., Charissé, K., et al. (2019) · Bioanalysis · doi:10.4155/bio-2019-0118 · Cited by 28
Bioresponsive polyplexes – chemically programmed for nucleic acid delivery
Hager, S., & Wagner, E. (2018) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2018.1526922 · Cited by 26
Basiri, B., Xie, F., Wu, B., Humphreys, S. C., Lade, J. M., Thayer, M. B., Yamaguchi, P., Florio, M., & Rock, B. M. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.07.012 · Cited by 26
Ng, B., Cash-Mason, T., Wang, Y., Seitzer, J. L., Burchard, J., Brown, D., Dudkin, V., Davide, J. P., Jadhav, V., Sepp‐Lorenzino, L., et al. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.02.013 · Cited by 27
Self-citationPerspectives, Issues and Solutions in RNAi Therapy: the Expected and the Less Expected
Aigner, A. M. (2019) · Nanomedicine · doi:10.2217/nnm-2019-0321 · Cited by 25
Systematic analysis of siRNA and mRNA features impacting fully chemically modified siRNA efficacy
Davis, S. M., Hildebrand, S. R., MacMillan, H. J., Monopoli, K. R., Buchwald, J. E., Sousa, J., Cooper, D., Ly, S., Echeverria, D., McHugh, N., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf479 · Cited by 26
Chemical strategies for strand selection in short-interfering RNAs
Varley, A., & Desaulniers, J. (2021) · RSC Advances · doi:10.1039/d0ra07747j · Cited by 26
Maguregui, A., & Abe, H. (2020) · ChemBioChem · doi:10.1002/cbic.202000009 · Cited by 26
Current Approaches to Epigenetic Therapy
Griazeva, E. D., Fedoseeva, D. M., Radion, E. I., Ershov, P. V., Meshkov, I. O., Semyanihina, A. V., Makarova, A. S., Makarov, V. V., Yudin, V. S., Keskinov, A. A., et al. (2023) · Epigenomes · doi:10.3390/epigenomes7040023 · Cited by 23
Advances in structural-guided modifications of siRNA
Li, Q., Dong, M., & Chen, P. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117825 · Cited by 27
Davis, S. M., Sousa, J., Vangjeli, L., Hassler, M. R., Echeverria, D., Knox, E. G., Turanov, A. A., Alterman, J. F., & Khvorova, A. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.05.010 · Cited by 23
Impact of Serum Proteins on the Uptake and RNAi Activity of GalNAc-Conjugated siRNAs
Agarwal, S., Allard, R., Darcy, J., Chigas, S., Gu, Y., Nguyen, T. M., Bond, S., Chong, S., Wu, J., & Janas, M. M. (2021) · Nucleic Acid Therapeutics · doi:10.1089/nat.2020.0919 · Cited by 24
Ye, D., Cruz‐López, E. O., Tu, H.-C., Zlatev, I., & Danser, A. H. J. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.319897 · Cited by 25
O′Shea, J., Theile, C. S., Das, R. S., Babu, I. R., Charissé, K., Manoharan, M., Maier, M. A., & Zlatev, I. (2018) · Tetrahedron · doi:10.1016/j.tet.2018.09.008 · Cited by 22
Self-citationLigand Conjugated Multimeric siRNAs Enable Enhanced Uptake and Multiplexed Gene Silencing
Brown, J. M., Dahlman, J. E., Neuman, K. K., Prata, C. A. H., Krampert, M., Hadwiger, P., & Vornlocher, H. (2019) · Nucleic Acid Therapeutics · doi:10.1089/nat.2019.0782 · Cited by 23
Mikami, A., Erande, N. D., Matsuda, S., Kel’in, A. V., Woods, L. B., Chickering, T., Pallan, P. S., Schlegel, M. K., Zlatev, I., Egli, M., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa750 · Cited by 24
Self-citationYe, X., Holland, R., Wood, M., Pasetka, C., Palmer, L., Samaridou, E., McClintock, K., Borisevich, V., Geisbert, T. W., Cross, R. W., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.09.009 · Cited by 23
Unlocking the Potential of Chemically Modified Nucleic Acid Therapeutics
Gao, J., Nutan, B., Gargouri, D., Pisal, N. D., Do, V., Zubair, M., Alanzi, H., Wang, H., Lee, D., Joshi, N., et al. (2024) · Advanced Therapeutics · doi:10.1002/adtp.202400231 · Cited by 20
Murray, J. K., Long, J., Liu, L., Singh, S., Pruitt, D., Ollmann, M. M., Swearingen, E., Hardy, M., Homann, O. R., Wu, B., et al. (2021) · Nucleic Acid Therapeutics · doi:10.1089/nat.2021.0026 · Cited by 20
Future directions for medicinal chemistry in the field of oligonucleotide therapeutics
Hall, J. (2023) · RNA · doi:10.1261/rna.079511.122 · Cited by 21
RNA nanomedicine in liver diseases
Bakrania, A. K., Mo, Y., Zheng, G., & Bhat, M. (2023) · Hepatology · doi:10.1097/hep.0000000000000606 · Cited by 21
Yamada, K., Hildebrand, S. R., Davis, S. M., Miller, R., Conroy, F., Sapp, E., Caiazzi, J., Alterman, J. F., Roux, L., Echeverria, D., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab1126 · Cited by 19
Smidt, J. M., Lykke, L., Stidsen, C. E., Pristovšek, N., & Gothelf, K. V. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad1015 · Cited by 18
Advanced siRNA delivery in combating hepatitis B virus: mechanistic insights and recent updates
Nguyen, L., Nguyen, T. T., Kim, J., & Jeong, J. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-03004-3 · Cited by 24
Berk, C., Civenni, G., Wang, Y., Steuer, C., Catapano, C. V., & Hall, J. (2020) · Nucleic Acid Therapeutics · doi:10.1089/nat.2020.0852 · Cited by 19
Miao, J., Gao, P., Li, Q., He, K., Zhang, L., Wang, J., & Huang, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011227 · Cited by 18
Harumoto, T., Iwai, H., Tanigawa, M., Kubo, T., Atsumi, T., Tsutsumi, K., Takashima, M., Destito, G., Soloff, R. S., Tomizuka, K., et al. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.1c00652 · Cited by 18
Chemical Modifications in RNA Interference and CRISPR/Cas Genome Editing Reagents
Lennox, K. A., & Behlke, M. A. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0290-4_2 · Cited by 17
Binzel, D. W., Guo, S., Yin, H., Lee, T. J., Liu, S., Shu, D., & Guo, P. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.07.021 · Cited by 17
Kajino, R., Maeda, Y., YOSHIDA, H., Yamagishi, K., & Ueno, Y. (2019) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.8b03277 · Cited by 17
Kliuchnikov, E., Maksudov, F., Zuber, J., Hyde, S., Castoreno, A. B., Waldron, S., Schlegel, M. K., Marx, K. A., Maier, M. A., & Barsegov, V. A. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102415 · Cited by 17
Self-citationTargeted delivery of BACE1 siRNA for synergistic treatment of Alzheimer's disease
Li, Z., Yang, J., Li, J., Zhao, S., Jiang, S., Liu, W., Li, X., Zhang, S.-M., Du, H., Ni, J., et al. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00503-7 · Cited by 20
Huang, E. J.-C., Wu, M., Wang, T.-J., Huang, T., Li, Y., & Lee, C. (2022) · Aging and Disease · doi:10.14336/ad.2022.1215 · Cited by 16
Inferring Half-Lives at the Effect Site of Oligonucleotide Drugs
Jansson‐Löfmark, R., & Gennemark, P. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0739 · Cited by 17
Kubo, T., Nishimura, Y., Sato, Y., Yanagihara, K., & Seyama, T. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00847 · Cited by 15
To Conjugate or to Package? A Look at Targeted siRNA Delivery Through Folate Receptors
Salim, L., & Desaulniers, J. (2020) · Nucleic Acid Therapeutics · doi:10.1089/nat.2020.0893 · Cited by 15
Saburi, A., Kahrizi, M. S., Naghsh, N., Etemadi, H., İlhan, A., Adili, A., Ghoreishizadeh, S., Tamjidifar, R., Akbari, M., & Ercan, G. (2022) · Journal of Ovarian Research · doi:10.1186/s13048-022-01012-1 · Cited by 15
RNA interference to enhance radiation therapy: Targeting the DNA damage response
Ratnayake, G., Bain, A. L., Fletcher, N. L., Howard, C. B., Khanna, K. K., & Thurecht, K. J. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.09.011 · Cited by 15
Zhong, Y., Ashley, C. L., Steain, M. C., & Ataide, S. F. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.975322 · Cited by 15
Andersson, P. U., & den Besten, C. (2019) · Royal Society of Chemistry eBooks · doi:10.1039/9781788015714-00474 · Cited by 16
siRNA Therapeutics for the Treatment of Hereditary Diseases and Other Conditions: A Review
Shevelev, A. B., Pozdniakova, N. V., Generalov, E. A., & Tarasova, O. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178651 · Cited by 16
Lipid Nanoparticle-Mediated Delivery of miRNA Mimics to Myeloid Cells
Kang, E. Y., & Kortylewski, M. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3331-1_24 · Cited by 15
Repositioning the antihistamine ebastine as an intracellular siRNA delivery enhancer
Muntean, C., Blondeel, E., Harinck, L., Pednekar, K. P., Prakash, J., Wever, O. D., Chain, J. L., Smedt, S. C. D., Remaut, K., & Raemdonck, K. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123348 · Cited by 13
Development of siRNA Therapeutics for the Treatment of Liver Diseases
Holm, A., Løvendorf, M. B., & Kauppinen, S. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1298-9_5 · Cited by 13
Yang, Q., Humphreys, S. C., Lade, J. M., & Li, A. P. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114374 · Cited by 13
Design of siRNA Bioconjugates for Efficient Control of Cancer-Associated Membrane Receptors
Lee, J. W., Choi, J., Kim, E. H., Choi, J., Kim, S. H., & Yang, Y. (2023) · ACS Omega · doi:10.1021/acsomega.3c05395 · Cited by 12
Non-viral delivery of RNA for therapeutic T cell engineering
Berdecka, D., Smedt, S. C. D., Vos, W. H. D., & Braeckmans, K. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115215 · Cited by 14
Assembling the RNA therapeutics toolbox
Teng, M., Xia, Z. J., Lo, N., Daud, K., & He, H. H. (2024) · Medical Review · doi:10.1515/mr-2023-0062 · Cited by 12
Artificial peptides for antitumoral siRNA delivery
Luo, J., Wagner, E., & Wang, Y. (2020) · Journal of Materials Chemistry B · doi:10.1039/c9tb02756d · Cited by 12
Extension in the approaches to treat cancer through siRNA system: a beacon of hope in cancer therapy
Rautela, I., Sharma, A., Dheer, P., Thapliyal, P., Sahni, S., Sinha, V. B., & Sharma, M. D. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-00995-6 · Cited by 12
RNAi-mediated rheostat for dynamic control of AAV-delivered transgenes
Subramanian, M. P., McIninch, J., Zlatev, I., Schlegel, M. K., Kaittanis, C., Nguyen, T. M., Agarwal, S., Racie, T., Alvarado, M. A., Wassarman, K., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37774-5 · Cited by 11
Self-citationCholesterol Conjugates of Small Interfering RNA: Linkers and Patterns of Modification
Chernikov, I. V., Ponomareva, U. A., Meschaninova, M. I., Bachkova, I. K., Vlassov, V. V., Аркадьевна, З. М., & Chernolovskaya, E. L. (2024) · Molecules · doi:10.3390/molecules29040786 · Cited by 10
Advancing hypertension management: the role of zilebesiran as an siRNA therapeutic agent
Siddiqui, E., Siddiqui, A. H., Moeed, A., Laique, F., Najeeb, H., & Hasibuzzaman, M. A. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002696 · Cited by 14
Structural basis for gene silencing by siRNAs in humansPreprint
Sarkar, S., Gebert, L. F. R., & MacRae, I. J. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.05.627081 · Cited by 11
Important Aspects of siRNA Design for Optimal Efficacy In Vitro and In Vivo
Bhakta-Yadav, M. S., & Brown, T. L. (2025) · International Journal of Cell Biology · doi:10.1155/ijcb/6663816 · Cited by 11
Evaluating the oral delivery of GalNAc-conjugated siRNAs in rodents and non-human primates
Yu, M., Qin, J., Liu, X., Ramsden, D., Williams, B., Zlatev, I., Guenther, D. C., Matsuda, S., Tymon, R. E., Darcy, J., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae350 · Cited by 13
Self-citationsiRNA-based strategies to combat drug resistance in gastric cancer
Khaleel, A. Q., Alshahrani, M. Y., Rizaev, J. A., Malathi, H., Devi, S., Pramanik, A., Mustafa, Y. F., Hjazi, A. M., Muazzamxon, I., & Husseen, B. (2024) · Medical Oncology · doi:10.1007/s12032-024-02528-w · Cited by 10
Asialoglycoprotein receptor 1: a multifaceted receptor in the liver and cardiovascular system
Xiao, X., Nie, Y., & Leng, Y. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1653452 · Cited by 14
Li, G., Gong, J., Cao, S., Wu, Z., Cheng, D., Zhu, J. X., Huang, X., Tang, J., Yuan, Y., Cai, W.-Q., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.742149 · Cited by 10
Identification of selective and non-selective C9ORF72 targeting in vivo active siRNAs
Gilbert, J. W., Kennedy, Z., Godinho, B. M. D. C., Summers, A., Weiss, A., Echeverria, D., Bramato, B. M., McHugh, N., Cooper, D., Yamada, K., et al. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102291 · Cited by 8
Inverted chimeric RNAi molecules synergistically cotarget MYC and KRAS in KRAS-driven cancers
Chareddy, Y. S., Huggins, H. P., Sahoo, S. S., Stanland, L. J., Gutierrez-Ford, C., Whately, K. M., Edatt, L., Azam, S. H., Fleming, M. C., Im, J., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci187204 · Cited by 11
Splice-switching small molecules: A new therapeutic approach to modulate gene expression
Taladriz‐Sender, A., Campbell, E., & Burley, G. A. (2019) · Methods · doi:10.1016/j.ymeth.2019.06.011 · Cited by 9
Geisler, A., Dieringer, B., Elsner, L., Klingel, K., Klopfleisch, R., Vornlocher, H., Kurreck, J., & Fechner, H. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.05.016 · Cited by 9
Tolksdorf, B., Heinze, J., Niemeyer, D., Röhrs, V., Berg, J., Drosten, C., & Kurreck, J. (2024) · Antiviral Research · doi:10.1016/j.antiviral.2024.105879 · Cited by 9
Lehoux, D. E., Far, A. R., Kallend, D. G., Wijngaard, P. L. J., & Zerler, B. R. (2022) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2022.115978 · Cited by 9
Kubo, T., Nishimura, Y., Hatori, Y., Akagi, R., Mihara, K., Yanagihara, K., & Seyama, T. (2018) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13454 · Cited by 9
Jeon, J. Y., Ayyar, V. S., Ouchi, S., Fabbrini, E., Koshkina, A., Prusakiewicz, J. J., Dallas, J., Yang, T., Jian, W., Kang, L., et al. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.6174 · Cited by 9
Discovery of long-acting APOC3 siRNA for treating patients with hypertriglyceridemia
Prakash, T. P., Mullick, A. E., Riney, S., Yu, J., Nikan, M., Quirk, C., Crutchfield, A., Damle, S. S., Klein, S., & Swayze, E. E. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf1063 · Cited by 8
Dry powder inhalation of siRNA therapeutics: Emerging strategies for pulmonary gene silencing
Lu, Y., Zhao, M., Li, M., Liu, N., Wang, Z., Zhang, H., Duan, S., Wu, J., & Zheng, A. (2025) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2025.104076 · Cited by 9
Grondek, J. F., Huffman, K., Lee, E. J., Cavichini, M., Warter, A., Kalaw, F. G. P., Heinke, A., Fan, R., Cheng, L., Sailor, M. J., et al. (2022) · Nanomedicine · doi:10.2217/nnm-2022-0255 · Cited by 10
Adapting ADME and Pharmacokinetic Analysis to the Next Generation of Therapeutic Modalities
Hochman, J. H. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.09.057 · Cited by 8
siRNA Design and GalNAc-Empowered Hepatic Targeted Delivery
Lu, M., Zhang, M., Hu, B., & Huang, Y. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1298-9_6 · Cited by 8
Chernikov, I. V., Ponomareva, U. A., Meschaninova, M. I., Bachkova, I. K., Teterina, A. A., Gladkikh, D. V., Savin, I. A., Vlassov, V. V., Аркадьевна, З. М., & Chernolovskaya, E. L. (2023) · Nucleic Acid Therapeutics · doi:10.1089/nat.2023.0051 · Cited by 8
In vivo expansion of gene-targeted hepatocytes through transient inhibition of an essential gene
Giorgi, M. D., Park, S. H., Castoreno, A. B., Cao, M., Hurley, A. E., Saxena, L., Chuecos, M. A., Walkey, C. J., Doerfler, A. M., Furgurson, M. N., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adk3920 · Cited by 9
Self-citationSyringable Microcapsules for Sustained, Localized, and Controllable siRNA Delivery
Liu, Y., Wang, Y., Kulkarni, R. A., Wegiel, L. A., Lee, B., Bedingfield, S. K., & Weitz, D. A. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c12805 · Cited by 7
Chemical Modifications in Nucleic Acid Therapeutics
Lennox, K. A., Young, R. C., & Behlke, M. A. (2025) · Methods in molecular biology · doi:10.1007/978-1-0716-4742-4_3 · Cited by 8
Metadata
- Authors
- Foster, D. J., Brown, C. R., Shaikh, S., Trapp, C., Schlegel, M. K., Qian, K., Sehgal, A., Rajeev, K. G., Jadhav, V., Manoharan, M., Kuchimanchi, S., Maier, M. A., & Milstein, S.
- Affiliations
- Alnylam Pharmaceuticals (United States) (US)
- Corresponding author
- Milstein, Stuart
- ORCID
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2018-03
- Volume
- 26
- Issue
- 3
- Pages
- 708-717
- ISSN
- 1525-0016 (ISSN-L)
- PMC
- PMC5910670
- OpenAlex
- W2781906140
- Cited by
- 325
- References
- 32
- Citations by year
- 2026: 41 · 2025: 46 · 2024: 49 · 2023: 34 · 2022: 34 · 2021: 37 · 2020: 43 · 2019: 24 · 2018: 17
- FWCI
- 10.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Molecular Therapy (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA and Nucleic Acid Chemistry
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Keywords
- siRNA design, RNAi therapeutics, asialoglycoprotein receptor, siRNA stability, non-human primates, subcutaneous administration
- MeSH terms
- Acetylgalactosamine, Animals, Gene Expression Regulation, Liver, Male, Mice, Transgenic, RNA, Messenger, Gene Silencing, Hepatocytes, RNA Interference, RNA, Small Interfering, Mice, Argonaute Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
